MBQ-167 is a potent inhibitor of Rac and Cdc42, which are small GTPases involved in cell motility, proliferation, and survival. Its primary application is in cancer research, where it is used to study the role of these GTPases in tumor growth and metastasis. By inhibiting Rac and Cdc42, MBQ-167 can effectively reduce cancer cell invasion and migration, making it a valuable tool for understanding and potentially treating aggressive cancers, particularly those with high metastatic potential. Additionally, it is used in preclinical studies to explore its potential as a therapeutic agent in targeting pathways that drive cancer progression.